XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.81

-4.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (16352)	10/12/2003 11:13:46 AM
From: aknahow	Read Replies (1) of 17367

Robert, original gelonin work failed. It was brought back with new improved twist and then Xoma decided not to bring it clinic as they thought they would. The $10 million was a payment for work in progress. It was not a pure profit penalty. Even so it was and is $10 million, but again it pays Xoma for expenses incurred. I love BPI but does Xoma? You are good at finding continuation of old patents but reluctant to answer why Xoma is not even funding the probes. If Xoma had a real interest where are the clinical trials on fungus? Why does Xoma cite Aiello's work done years ago when he and the Harvard eye clinic appear to have moved on?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next